<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02069899</url>
  </required_header>
  <id_info>
    <org_study_id>NI-0501-05</org_study_id>
    <nct_id>NCT02069899</nct_id>
  </id_info>
  <brief_title>Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody</brief_title>
  <official_title>A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovImmune SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Supported by a grant of the 7th framework programme &quot;FP7&quot; from the European Committee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NovImmune SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      International, multicenter, long-term, follow-up study that will enroll HLH patients who have
      received NI-0501 in a previous clinical trial, in the context of the clinical development
      program for NI-0501
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to monitor the long-term safety profile of patients who have
      previously received at least one dose of NI-0501, including survival at several time points
      after the administration of NI-0501.

      Moreover to study the elimination profile of NI-0501 and to assess the immunogenicity of
      NI-0501.

      Furthermore in the event that patients, upon request of the treating physician, will be
      maintained on NI-0501 treatment beyond the foreseen 8 weeks, NI-0501 safety, tolerability,
      efficacy and PK profile will be closely monitored in these patients until treatment
      discontinuation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2014</start_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Endpoints</measure>
    <time_frame>Up to 12 months post transplant or post last dose of NI-0501</time_frame>
    <description>The incidence, intensity, possible relationship to NI-0501 and outcomes of adverse events, serious and non-serious, will be assessed throughout the study.
Vital signs, physical examination and laboratory values: evolution over time.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Efficacy endpoints</measure>
    <time_frame>Pre transplant, 30, 60, 100 days and 6, 12 months post transplant or post last dose of NI-0501</time_frame>
    <description>Survival</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Up to 6 months after last NI-0501 infusion</time_frame>
    <description>- NI-0501 elimination profile</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>Up to 6 months after last NI-0501 infusion</time_frame>
    <description>IFNγ total, as long as NI-0501 can be measured
IFNγ free, as soon as NI-0501 is not detectable
Exploratory parameters/disease markers</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Up to 6 months after last NI-0501 infusion</time_frame>
    <description>Presence of anti-drug antibodies (i.e. ADAs)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Hemophagocytic Lymphohistiocytosis</condition>
  <arm_group>
    <arm_group_label>NI-0501 only in case is requested</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>NI-0501, in the event that, upon request of the treating physician, NI-0501 treatment needs to be prolonged beyond Week 8 foreseen in the previous protocol, patients will continue receiving NI-0501 in the context of this study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NI-0501</intervention_name>
    <description>In the event that NI-0501 treatment needs to be prolonged beyond Week 8 foreseen in the previous study, and upon request of the treating physician, patients will continue receiving NI-0501 in the context of this study.</description>
    <arm_group_label>NI-0501 only in case is requested</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Having received at least one dose of NI-0501.

          -  Having signed the Informed Consent by the patient or the patient's legal
             representative(s), as applicable, with the assent of patients who are legally capable
             of providing it.

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Veronica Asnaghi, MD</last_name>
    <phone>+41 61 201 13 31</phone>
    <email>veronica.asnaghi@sobi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045-7106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute (DFCI)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital - Division of Immunobiology</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexei Grom, MD</last_name>
      <phone>513-636-4676</phone>
      <email>alexi.grom@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Alexei Grom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre Quartier Dit Maire, MD</last_name>
      <phone>33144494828</phone>
    </contact>
    <investigator>
      <last_name>Pierre Quartier Dit Maire, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital Münster Department of Pediatric Hematology and Oncology</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Iscss Istituto Giannina Gaslini</name>
      <address>
        <city>Genova</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angelo Ravelli, MD</last_name>
      <phone>+3901056362578</phone>
    </contact>
    <investigator>
      <last_name>Angelo Ravelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Gerardo - Centro di Emato-Oncologia Pediatrica</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Padova - Clinica di Oncoematologia Pediatrica</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesu</name>
      <address>
        <city>Rome</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesù - UO Reumatologia</name>
      <address>
        <city>Rome</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrizio de Benedetti, MD</last_name>
      <phone>00 39 06 6859 2309 2659</phone>
      <email>fabrizio.debenedetti@opbg.net</email>
    </contact>
    <investigator>
      <last_name>Fabrizio de Benedetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Donna Bambino - U.O.C. Oncoematologia Pediatrica</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron Servei de Hematologia i Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08900</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu</name>
      <address>
        <city>Esplugues De Llobregat</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordi Anton, MD</last_name>
      <phone>+34932804000</phone>
    </contact>
    <investigator>
      <last_name>Jordi Anton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Niño Jesús Servicio de Hemato-Oncología Pediátrica</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Brogan, MD</last_name>
      <phone>020 7405 9200</phone>
      <phone_ext>7887</phone_ext>
    </contact>
    <investigator>
      <last_name>Paul Brogan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital - Department of Haematology</name>
      <address>
        <city>London</city>
        <zip>WC1N3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Czech Republic</country>
    <country>Turkey</country>
  </removed_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>December 23, 2013</study_first_submitted>
  <study_first_submitted_qc>February 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2014</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemophagocytic lymphohistiocytosis (HLH) previously treated with NI-0501</keyword>
  <keyword>Emapalumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphohistiocytosis, Hemophagocytic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

